Faruqui Saamia, Shanbhogue Krishna, Jacobson Ira M
Department of Medicine, NYU Grossman School of Medicine, New York, New York.
Department of Radiology, NYU Grossman School of Medicine, New York, New York.
Gastroenterol Hepatol (N Y). 2022 Jul;18(7):380-387.
Multiple studies and extensive clinical experience have shown that COVID-19 can impact the hepatobiliary system, with most reports describing primarily hepatocellular injury with elevations of aspartate aminotransferase and alanine aminotransferase. In addition to hepatocellular injury, recent literature has described a pattern of severe biliary tract injury resulting in patients with COVID-19. This novel syndrome, termed COVID-19 cholangiopathy, may have severe consequences for affected patients. This article will examine the literature describing this novel entity, its relationship to secondary sclerosing cholangitis, clinical outcomes, and proposed mechanisms underlying this form of biliary injury.
多项研究和广泛的临床经验表明,新型冠状病毒肺炎(COVID-19)可影响肝胆系统,大多数报告主要描述的是伴有天冬氨酸转氨酶和丙氨酸转氨酶升高的肝细胞损伤。除肝细胞损伤外,最近的文献还描述了COVID-19患者出现的严重胆道损伤模式。这种新综合征被称为COVID-19胆管病,可能会给受影响的患者带来严重后果。本文将探讨描述这种新实体的文献、其与继发性硬化性胆管炎的关系、临床结局以及这种胆道损伤形式的潜在机制。